NYSE: AGE - AgeX Therapeutics, Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart AgeX Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.

more details
Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-11-29
ISIN US00848H1086
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.agexinc.com
Цена ао 11.1
Change price per day: 0% (11.1)
Change price per week: 0% (11.1)
Change price per month: 0% (11.1)
Change price per 3 month: 0% (11.1)
Change price per half year: 0% (11.1)
Change price per year: -50.27% (22.32)
Change price per 3 year: +1 508.7% (0.69)
Change price per 5 year: +692.86% (1.4)
Change price per year to date: 0% (11.1)
All parameters

Underestimation

Title Value Grade
P/S 2.98 6
P/BV 0.079 10
P/E 0 0
EV/EBITDA -0.4521 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -123.72 0
ROE, % -270.67 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4441 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -91.65 0
Yield Ebitda, % -15.27 0
Yield EPS, % 4028.55 10
Total: 2.6
More

Institutions Volume Share, %
Broadwood Capital, Inc. 2997156 7.9
Vanguard Group Inc 701755 1.85
Sigma Planning Corp 286425 0.75
Prescott General Partners LLC 185185 0.49
Bridgeway Capital Management, Inc. 144770 0.38
Geode Capital Management, LLC 140994 0.37
Blackrock Inc. 124301 0.33
Strategic Wealth Investment Group, LLC 97375 0.26
Creative Planning 70700 0.19
Northern Trust Corporation 31533 0.08

ETFShare, %Profitability for 1 year, %Dividends, %
Sprott Uranium Miners ETF 0.42828 343.52 3.27507
Global X Uranium ETF 0.21695 7.84 1.74266
0.33175.682.51



Head Job title Payment Year of birth
Ms. Eun-Jae Park CPA Chief Financial Officer 295.29k 1972 (53 years)
Dr. Ivan Labat Chief Information Officer N/A
Ms. Judith Segall Secretary N/A 1953 (72 years)

Address: United States, Alameda. CA, 1101 Marina Village Parkway - open in Google maps, open in Yandex maps
Website: https://www.agexinc.com